(Total Views: 1312)
Posted On: 04/04/2020 5:09:44 AM
Post# of 155726
I doubt they would take the time to read everything, so a short description at the top would help greatly.
The most significant patients recovering on leronlimab given low chance of survival based on recent studies. Second is Bruce Patterson testing patients to verify the cytokine storm, which sends millions of immune cells to fight the virus in the lungs in a scorched earth method, destroying everything in their path, is being returned to normal within a couple days after given leronlimab, proving MOA.
Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn explains: “Leronlimab inhibits migration of Tregs, which can inhibit the innate immune response against pathogens, into areas of inflammation. Most importantly, the migration of macrophages and the release of inflammatory cytokines including TNF and IL-6 (cytokine storm) is what causes the profound damage in the lungs in some patients. Leronlimab binding to CCR5 changes the macrophages migration and cytokine production. Taken together, these activities may reduce the morbidity and mortality in moderate to severe cases of COVID-19. IncellDx has developed a suite of diagnostics to monitor these effects of leronlimab on the immune system in these critical patients.”
Image of issue:
The most significant patients recovering on leronlimab given low chance of survival based on recent studies. Second is Bruce Patterson testing patients to verify the cytokine storm, which sends millions of immune cells to fight the virus in the lungs in a scorched earth method, destroying everything in their path, is being returned to normal within a couple days after given leronlimab, proving MOA.
Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn explains: “Leronlimab inhibits migration of Tregs, which can inhibit the innate immune response against pathogens, into areas of inflammation. Most importantly, the migration of macrophages and the release of inflammatory cytokines including TNF and IL-6 (cytokine storm) is what causes the profound damage in the lungs in some patients. Leronlimab binding to CCR5 changes the macrophages migration and cytokine production. Taken together, these activities may reduce the morbidity and mortality in moderate to severe cases of COVID-19. IncellDx has developed a suite of diagnostics to monitor these effects of leronlimab on the immune system in these critical patients.”
Image of issue:
(3)
(0)
